0000000000465821

AUTHOR

M.r. Meli

showing 1 related works from this author

Patients' Acceptability of Different Fentanyl Products for Breakthrough Cancer Pain

2014

OTFC (6) 1.7 (0.5) 1.5 (0.5) 2.0 (0.6) 1.5 (0.8) 1.5 (0.5) 33.1 (43.5) FBT (19) 2.0 (0.6) 2.0 (0.7) 1.8 (0.7) 1.8 (0.8) 1.9 (0.7) 15.9 (7.3) SLF (37) 2.1 (0.5) 2.2 (0.4) 1.8 (0.4) 2.0 (0.6) 2.1 (0.5) 16.7 (12.5) INFS (7) 2.1 (0.4) 2.1 (0.4) 2.0 (0.6) 2.0 (0.8) 2.0 (0.8) 15.7 (13.7) PFEN (11) 2.4 (0.5) 2.2 (0.4) 1.8 (0.4) 1.9 (0.7) 2.1 (0.5) 15.0 (13.7) P 0.120 0.043* 0.870 0.595 0.178 0.015x *,x Oral transmucosal fentanyl was significantly considered to be more problematic.

Settore MED/06 - Oncologia Medicabusiness.industryBreakthrough PainBreakthrough PainPatient Acceptance of Health CareSettore MED/42 - Igiene Generale E ApplicatafentanylFentanylbreakthrough cancer painBTPOncologyNeoplasmsAnesthesiaAdministration MucosalHumansMedicineRadiology Nuclear Medicine and imagingpatient's preferencefentanyl; breakthrough cancer pain; BTP; patient's preferencebusinessCancer painmedicine.drugClinical Oncology
researchProduct